CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Major infections after bypass surgery and stenting: an overlooked but fatal complication Coronary Plaque Features on CTA Can Identify Patients at Increased Risk of Cardiovascular Events Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes Management of Patients With NSTE-ACS: A Comparison of the Recent AHA/ACC and ESC Guidelines Randomized Comparison of Everolimus- and Zotarolimus-Eluting Coronary Stents With Biolimus-Eluting Stents in All-Comer Patients A Novel Familial Cardiac Arrhythmia Syndrome with Widespread ST-Segment Depression Percutaneous Coronary Intervention for Chronic Total Occlusion—The Michigan Experience: Insights From the BMC2 Registry Spontaneous Coronary Artery Dissection: JACC State-of-the-Art Review

Review Article2017 Oct 24;70(17):2186-2200.

JOURNAL:J Am Coll Cardiol. Article Link

Biological Phenotypes of Heart Failure With Preserved Ejection Fraction

Lewis GA, Schelbert EB, Miller CA et al. Keywords: diastolic dysfunction; ejection fraction; heart failure; heart failure with preserved ejection fraction; myocardial fibrosis; titin

ABSTRACT

Heart failure with preserved ejection fraction (HFpEF) involves multiple pathophysiological mechanisms, which result in the heterogeneous phenotypes that are evident clinically, and which have potentially confounded previous HFpEF trials. A greater understanding of the in vivo human processes involved, and in particular, which are the causes and which are the downstream effects, may allow the syndrome of HFpEF to be distilled into distinct diagnoses based on the underlying biology. From this, specific interventions can follow, targeting individuals identified on the basis of their biological phenotype. This review describes the biological phenotypesof HFpEF and therapeutic interventions aimed at targeting these phenotypes.